520MO Safety and efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic cervical cancer (R/M Cx Ca) in checkmate 358

Anti–PD–1–based treatment (tx) is approved in 1st (1L)– and 2nd (2L)–line settings for programmed death ligand 1 (PD–L1)+ R/M Cx Ca; however, objective response rate (ORR) with single–agent tx is <15% (Chung et al SGO 2021 abstract). Here, we report safety and efficacy of NIVO ± IPI in pts with R/M Cx Ca in CheckMate 358 (NCT02488759), a phase 1/2 study of NIVO and NIVO–based combinations in virus–associated solid tumors.